NASDAQ:CRSP stock has undergone multiple analysts rating changes in the recent past.  NASDAQ:CRSP stock Target Raised by   Roth Capital on 6/19/2020. In a note to investors, the firm issued a new target price of $105.00. The analysts previously had $100.00 target price. Roth Capital’s price target would indicate a potential upside of 58.30% from the stock’s previous close.

Shares of NASDAQ:CRSP traded up $0.35 on Friday, reaching $67.69. 51360 shares of the stock traded hands, compared to its average volume of 967575. Shares of NASDAQ:CRSP started the day on up  at $67.69 on Friday. The firm’s 50 day moving average is $$881,875.00 and its 200 day moving average is $977,024.00.NASDAQ:CRSP  has a 12 month low of $67.44 and a 12 month high of $74.00. While on yearly highs and lows, NASDAQ:CRSP today has traded high as $68.75 and has touched $67.44 on the downward trend.

NASDAQ:CRSP Earnings and What to expect: 

954,317

Crispr Therapeutics last released its earnings data on April 28th, 2020. The reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.10. The firm earned $0.16 million during the quarter, compared to analysts’ expectations of $3.04 million. Its revenue for the quarter was down 52.1% on a year-over-year basis. Crispr Therapeutics has generated $1.17 earnings per share over the last year and currently has a price-to-earnings ratio of 89.8. Crispr Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 3rd, 2020 based off prior year’s report dates.

Latest Insiders Trading and Volume : 

  • Earnings for Crispr Therapeutics are expected to decrease in the coming year, from ($4.51) to ($5.22) per share. The P/E ratio of Crispr Therapeutics is 89.79, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.37. The P/E ratio of Crispr Therapeutics is 89.79, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.13. Crispr Therapeutics has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
  • On Insider Ownership Percentage: 21.40% Samarth Kulkarni 6/1/2020 CEO Sell at average share price of 17,275 which equates to $64.68 in money value.
  • On 188,801 Samarth Kulkarni 5/20/2020 CEO Sell at average price of  10,693 with total value of : $65.28
  • On 175,833 Rodger Novak 5/19/2020 President Sell at average price of  50,000 with total value of : $65.00
  • See More Analyst Rating at: RATING

Other Analyst’s rating for NASDAQ:CRSP

  • 6/15/2020 – Crispr Therapeutics had its price target raised by analysts at Canaccord Genuity from $80.00 to $84.00. They now have a “buy” rating on the stock.
  • 6/12/2020 – Crispr Therapeutics had its “buy” rating re-affirmed by analysts at Piper Sandler. They now have a $104.00 price target on the stock.
  • 6/12/2020 – Crispr Therapeutics had its “buy” rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock.
  • 6/12/2020 – Crispr Therapeutics is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $84.00 price target on the stock.
  • See More Analyst Rating at: RATING

Other rating updates by Roth Capital: 

  • 6/18/2020 – Synchronoss Technologies had its “market perform” rating re-affirmed by analysts at Roth Capital. They now have a $9.00 price target on the stock.
  • 6/18/2020 – One Stop Systems had its “buy” rating re-affirmed by analysts at Roth Capital. They now have a $5.50 price target on the stock.
  • 6/18/2020 – PAR Technology was upgraded by analysts at Roth Capital from a “neutral” rating to a “buy” rating. They now have a $36.00 price target on the stock, up previously from $20.00.
  • 6/16/2020 – Soliton had its price target raised by analysts at Roth Capital from $14.00 to $16.00.
  • See More Analyst Rating at: RATING

NASDAQ:CRSP (CRSP) Moving Average Technical Analysis

5 day Moving Average is $NASDAQ : ID 26 And 5 day price change is $64.46 (764.00%)  with average volume for 5 day average is 0. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $766,000.00 and 20 day price change is $64.48 (55.00%) and average 20 day moving volume is 0. 50 day moving average is $881,875.00  and 50 day price change is $57.89 ( 2605.00%)  and with average volume for 50 days is : 1. 200 day moving average is $977,024.00  and 200 day price change is $53.37 (2252.00%)  and with average volume for 200 days is : 1.

See More Analyst Rating at: RATING



Source link